Omalizumab Benefits Patients With Chronic Inducible Urticaria

The recombinant anti-immunoglobulin E (IgE) monoclonal antibody omalizumab has 'substantial benefits' in treating various forms of chronic inducible urticaria (CIndU), according to a new systematic review.
Reuters Health Information

http://ift.tt/2uMMKly